Debut, a vertically integrated synthetic biology company that unlocks a new generation of cosmetic bioactive ingredients using the most advanced biomanufacturing approaches, announced that it will develop bio-identical and novel fragrance molecules, having closed a total of $40 million in its Series B funding led by BOLD, the venture capital fund of L'Oréal.

Debut is an unconventional innovation company, setting a new standard for the next generation of beauty. With breakthrough biotechnology, Debut's team of expert scientists and brand specialists work to develop novel bioactive skincare ingredients and products, including the launch of its first consumer brand through its scalable creation model. With a human-centric and climate-positive approach, Debut is committed to creating purposeful brands that push humanity forward.